Depot Medroxyprogesterone Acetate Can Be Safely Administered in Hypertensive Urgency
You can administer depot medroxyprogesterone acetate (DMPA) 150 mg IM to a patient with hypertensive urgency without needing to control blood pressure first. Progestin-only contraceptives like DMPA have no contraindications in hypertensive patients, even with uncontrolled hypertension.
Evidence-Based Rationale
Guideline Recommendations for DMPA in Hypertension
The French Society of Endocrinology guidelines explicitly address this scenario 1:
- For uncontrolled hypertension (≥160/100 mmHg): The advantages of progestin-only methods (including DMPA) outweigh theoretical or proven risks
- For controlled hypertension (<160/100 mmHg): There are no restrictions whatsoever on DMPA use
- For patients with cardiovascular disease history: DMPA advantages still outweigh risks
This stands in stark contrast to combined hormonal contraceptives (estrogen-progestin), which are contraindicated in uncontrolled hypertension 1.
Why DMPA is Safe in Hypertension
DMPA does not raise blood pressure. In fact, research demonstrates the opposite effect:
- A prospective study of 24 women receiving DMPA 150 mg showed mean blood pressure decreased from 124.1/79.4 to 115.6/73.2 mmHg over three months 2
- DMPA has no appreciable effects on blood pressure or thrombosis risk, giving it a distinct advantage over combined oral contraceptives 3
- Dose-response studies show either no effect or small dose-dependent reductions in blood pressure with medroxyprogesterone 4
Understanding Hypertensive Urgency Context
Hypertensive urgency (severely elevated BP without target organ damage) does not require immediate IV antihypertensive therapy 5, 6. Patients are often treated with oral medications to lower BP acutely, though evidence for this practice is limited 6. The key distinction is that hypertensive urgency lacks the acute end-organ damage that defines hypertensive emergency.
Clinical Algorithm
Step 1: Confirm hypertensive urgency (BP ≥180/120 mmHg without symptoms/signs of acute target organ damage)
Step 2: Verify patient desires contraception and has no other contraindications to DMPA (pregnancy, unexplained vaginal bleeding, breast cancer, severe liver disease)
Step 3: Administer DMPA 150 mg IM as scheduled - do not delay for blood pressure control
Step 4: Initiate or optimize antihypertensive therapy for long-term BP management as a separate issue
Step 5: Counsel patient that DMPA will not worsen hypertension and may modestly improve it
Important Caveats
- Combined hormonal contraceptives are different: Estrogen-containing methods ARE contraindicated in uncontrolled hypertension (≥160/100 mmHg) and relatively contraindicated in controlled hypertension 1
- Measure baseline BP: Always document blood pressure before DMPA administration, as this is the only clinical examination recommended before prescribing contraception 1
- Counsel about other side effects: Focus counseling on menstrual changes and potential weight gain, which are the main disadvantages of DMPA 3, not cardiovascular concerns
- Follow-up matters: Ensure patient has plan for ongoing hypertension management separate from contraceptive care
The evidence consistently supports that progestin-only contraception, including DMPA, represents the hormonal contraceptive of choice for hypertensive women 1.